BioNTech SE (BNTX) vs Incyte Corporation (INCY)
A side-by-side comparison of BioNTech SE and Incyte Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
BNTX
BioNTech SE
$96.06HealthcareDelayed quote: Sep 18, 2026, 4:00 PM EDT
INCY
Incyte Corporation
$125.31HealthcareDelayed quote: Sep 18, 2026, 4:00 PM EDT
Total return — BNTX vs INCY
growth of $100 · dividends reinvested · last 7yBNTX +588.3% (+31.7%/yr)INCY +62.5% (+7.2%/yr)BNTX compounded faster over this window
BNTX INCY
BNTX vs INCY: by the numbers
- •INCY is the larger company ($25.40B vs $24.13B market cap).
- •INCY is profitable (27.71% net margin) while BNTX runs a net loss (-62.98%).
- •BNTX grew revenue faster over the past five years (40.61% vs 16.43% CAGR).
Metrics side by side
Valuation
| Metric | BNTX | INCY |
|---|---|---|
| P/E ratio | N/A | 15.96 |
| Forward P/E | N/A | 33.31 |
| P/S ratio | 7.79 | 4.36 |
| P/B ratio | 1.19 | 4.00 |
| EV / EBITDA | N/A | 11.08 |
| FCF yield | 2.56% | 7.56% |
Profitability
| Metric | BNTX | INCY |
|---|---|---|
| Gross margin | 70.98% | 92.62% |
| Operating margin | -22.63% | 31.57% |
| Net margin | -62.98% | 27.71% |
| ROE | -9.62% | 25.41% |
| ROIC | -10.37% | 22.95% |
Growth (annualized)
| Metric | BNTX | INCY |
|---|---|---|
| Revenue CAGR (5Y) | 40.61% | 16.43% |
| EPS CAGR (5Y) | N/A | 21.19% |
| FCF CAGR (5Y) | N/A | 33.69% |
| Total return CAGR (5Y) | -22.43% | 11.30% |
Frequently asked
- Which has grown faster, BNTX or INCY?
- Over the past five years, BNTX grew revenue faster — BNTX at a 40.61% CAGR versus INCY at 16.43%.
- Is BNTX or INCY more profitable?
- INCY runs the higher net margin — BNTX at -62.98% versus INCY at 27.71%.
- How have BNTX and INCY total returns compared?
- Over the past 5 years, BNTX delivered -22.43% and INCY delivered 11.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Incyte P/E ratioBioNTech SE ROEIncyte ROEBioNTech SE operating marginIncyte operating marginBioNTech SE revenue growthIncyte revenue growthBioNTech SE free cash flowIncyte free cash flow
BioNTech SE & Incyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.